Trexquant Investment LP Bio N Tech Se Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$88.96 - $112.35 $234,943 - $296,716	2,641 New	2,641 $243,000
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $3.54 Million - $4.44 Million	28,915 Added 99.06%	58,105 $7.24 Million
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $3.46 Million - $5.43 Million	29,190 New	29,190 $4.38 Million
Q2 2022 Aug 11, 2022	BUY	$123.25 - $186.24 $10.1 Million - $15.2 Million	81,630 New	81,630 $12.2 Million
Q1 2022 May 13, 2022	SELL	$126.25 - $231.85 $2.44 Million - $4.48 Million	-19,330 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $4.19 Million - $7.01 Million	19,330 New	19,330 $4.98 Million
Q3 2021 Nov 12, 2021	SELL	$205.93 - $447.23 $281,712 - $611,810	-1,368 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$113.32 - $241.49 $155,021 - $330,358	1,368 New	1,368 $306,000
Q1 2021 May 13, 2021	SELL	$85.73 - $119.5 $2.16 Million - $3.01 Million	-25,198 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$72.71 - $129.54 $504,098 - $898,100	6,933 Added 37.96%	25,198 $2.05 Million
Q3 2020 Nov 06, 2020	BUY	$57.81 - $104.17 $1.06 Million - $1.9 Million	18,265 New	18,265 $1.26 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.3B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.